Our Companies & Assets

Discover the leading edge of our extraordinary pipeline: our advanced dermatology assets and the independent companies bringing these leading breakthroughs to commercial launch.

Propelling our pipeline to the market

Our most advanced energy-based skin health platforms are currently being prepared for launch by independently-funded companies purpose-built to commercialize assets developed at Blossom Innovations. Led by experienced commercial teams, and with our founders as active leaders, R2 Dermatology and AVAVA, Inc. are currently advancing two of our leading platforms to success in thriving global markets.

Simultaneously, we’re internally pursuing the launch of a breakthrough injection targeting system through our wholly-owned company S3Inject, using our own robust in-house product development resources.

R2 Dermatology

Independent company founded with our lead investor partner, Pansend Life Sciences, LLC (life sciences subsidiary of HC2 Holdings, Inc.)

Spun off to commercialize a groundbreaking Blossom Innovation cryotherapeutic platform, R2 Dermatology is poised to have a game-changing impact on aesthetic dermatology — a global, growing market currently valued at $22B.

Proprietary ICE controlled cooling technology

Contact system:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

Robotic spray system:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

The advanced R2 platform features two complementary technologies:

  • An FDA-cleared contact system indicated for the treatment of benign skin lesions
  • A first-in-world robotic spray system designed for overall skin lightening

Powered by ICE technology (Intelligent Crystallization of Epidermis), both technologies in the platform are designed to directly cool melanocytes in the dermo-epidermal junction — at precisely controlled time and temperature. Results are clear in 1-2 months and last for 4-6 months.

Expert leadership

Leading the launch is a seasoned leadership team with deep expertise in cryobiology and consumer branding experience – including CoolSculpting® and Fraxel® – and a world-class collective track record of success in aesthetics and beyond. To learn more, visit the homepage for R2 Dermatology.

 

 

AVAVA, Inc.

Independent company founded with our lead investor partner, Craig Drill Capital

Billions of people with skin of color have long had largely ineffective treatment options for their skin conditions. Long-lasting hyperpigmentation and melasma affect darker skin tones at a far higher rate, and safe skin rejuvenation remains a challenge for affected patients. AVAVA, Inc., is poised to offer them a revolutionary new treatment paradigm.

Next-gen 3D precision laser platform

Melasma/Post-inflammatory hyperpigmentation (PIH)

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

Rejuvenating skin of color:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

First developed in our Innovation Studio, the transformative new 3D laser technology in development at AVAVA, Inc., finally delivers precision therapy safe for all skin types. 

Safe and effective, with integrated visualization, this novel platform enables smart selective treatments and advanced machine learning capability for treatment optimization. The versatile and extendable platform enables the treatment of multiple clinical indications, including  a treatment of hyperpigmentation and melasma in skin of color — a market expected to reach $7.23B by 2026.

Next-gen 3D precision laser platform

A breakthrough in spatially selective laser treatment, the AVAVA platform is designed to focus therapeutic energy directly on hyperpigmentation below the epidermis. The laser’s unique optics reducing surface fluence and intensity, reducing damage to surrounding tissues, eliminating the need for surface-level contrast, and making the laser highly effective for patients with darker skin.

World-renowned management

The AVAVA commercial launch team is helmed by an unrivalled team of experts in photomedicine, dermatology, and the global business of energy-based therapeutics. 

To learn more, visit the homepage for AVAVA, Inc.

S3Inject

Millions of injections are administered every year, for a variety of aesthetic and therapeutic purposes from dermal fillers, to analgesia, to diagnostic aspirations. Despite the frequency of these procedures, they can still involve considerable risk and variability. The technology in development at S3Inject has the potential to transform the outcomes of these essential procedures for both injectors and patients alike.

Novel injection targeting system

Aesthetic injectables:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

Medical injectables:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

Vascular access:

Innovation Studio

Clinical Evaluation

Pre-Commercial

On Market

With over 3.5 million dermal filler procedures worldwide each year, every needle still represents a risk to be mitigated. Since typical injection areas for fillers are highly vascularized, puncturing and injecting into a blood vessel remains a concern for even experienced injectors. 

To mitigate that risk, we’ve developed a new “smart” needle system in development at S3Inject: a platform injection technology that can differentiate connective tissue, fat, blood vessels, and muscle. An ideal sensing system for targeted filler injections, it also has the potential to improve aspiration precision and avoidance of critical areas in a wide range of procedures. 

With no retraining requirements and a modular design that can be fitted to a variety of needles or cannulas, this new injection targeting system promises to be a significant advance for many different practitioners and a competitive advantage for many injectable products.

More groundbreaking advances are taking root

Inspired and guided by our SEED principles, we’re actively developing a remarkable range of disruptive innovations in dermatology and beyond. Check back soon or follow our News & Insights for the latest developments in our pipeline, companies, and dermatology market.